search
Back to results

Comparison of Reverse Remodeling and PVI Versus CFAE and/or Linear Lesions and PVI for Persistent AF

Primary Purpose

Persistent Atrial Fibrillation

Status
Withdrawn
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Ablation
Sponsored by
Valley Health System
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Persistent Atrial Fibrillation focused on measuring atrial fibrillation, persistent AF, catheter ablation, duration of 7 days to one year, with symptoms and failure of at least one antiarrhythmic drug

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Symptomatic persistent AF
  • Failure of class I antiarrhythmic drug or amiodarone to control AF

Exclusion Criteria:

  • Previous proarrhythmia to class III AAD including excessive QT prolongation or torsade-de-pointes
  • Previous AF ablation procedure
  • Congestive heart failure (NYHA III-IV functional class)
  • Left ventricle ejection fraction less than 35%
  • Left atrial diameter >55 mm
  • Unwillingness to participate

Sites / Locations

  • Valley Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Reverse remodeling

Standard ablation

Arm Description

Pretreatment with dofetilide or sotalol and restoration of sinus rhythm followed by PVI only ablation

PVI ablation with additional CFAE and/or linear LA ablation

Outcomes

Primary Outcome Measures

Freedom of atrial fibrillation/flutter

Secondary Outcome Measures

Full Information

First Posted
May 26, 2013
Last Updated
June 16, 2014
Sponsor
Valley Health System
search

1. Study Identification

Unique Protocol Identification Number
NCT01877473
Brief Title
Comparison of Reverse Remodeling and PVI Versus CFAE and/or Linear Lesions and PVI for Persistent AF
Study Type
Interventional

2. Study Status

Record Verification Date
June 2014
Overall Recruitment Status
Withdrawn
Why Stopped
No enrollment
Study Start Date
May 2013 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
September 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Valley Health System

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The hypothesis of this study is that by facilitating reverse atrial remodeling with maintenance of sinus rhythm in the weeks preceding ablation makes it feasible to perform a simple pulmonary vein isolation (PVI) with results equivalent or superior to more complex atrial ablation for patients with persistent AF.
Detailed Description
Atrial fibrillation (AF) is the most common cardiac disorder currently affecting 2.3 million U.S. adults with an expected increase in incidence to 5.6 million by the year 2050. Randomized clinical trials have shown that ablation was superior to antiarrhythmic drug (AAD) in maintaining sinus rhythm among patients with symptomatic predominantly paroxysmal AF. However the results for catheter ablation of persistent AF is much lower and more variable, ranging between 20-80%. Moreover there is no agreed-upon standard ablation approach. Prior studies suggest that pulmonary vein isolation (PVI) alone has an unacceptably low success rate so most laboratories supplement this approach with additional lesion sets. These include complex atrial fractionated electrograms ("CAFÉ"), autonomic denervation, and linear left atrial ablation at the roof and mitral isthmus, in an empirical manner or stepwise approach. However, these strategies are time consuming and prone to proarrhythmia, namely post-ablation atrial tachycardias which can occur with an incidence ranging from < 5 to 50%. The lower efficacy of PVI alone in persistent AF has been attributed to adverse electrical, molecular, and structural remodeling of the atria. Collectively, atrial remodeling decreases conduction velocity and the effective refractory period, and results in a shortened atrial wavelength, which increases the number and stability of reentrant wavelets. This can cause persistence of AF independent of a focal discharge. Standard PVI addresses the "focal discharge" or trigger from the PVs that initiates AF but not necessarily the underlying atrial substrate. Based on these concepts, we hypothesized that successful atrial reverse remodeling by temporary AAD therapy would facilitate the performance of PVI alone in patients with persistent AF. The utilization of reverse remodeling to enhance the efficiency, efficacy and safety of ablation of AF has not been tested in a randomized clinical trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Persistent Atrial Fibrillation
Keywords
atrial fibrillation, persistent AF, catheter ablation, duration of 7 days to one year, with symptoms and failure of at least one antiarrhythmic drug

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Reverse remodeling
Arm Type
Active Comparator
Arm Description
Pretreatment with dofetilide or sotalol and restoration of sinus rhythm followed by PVI only ablation
Arm Title
Standard ablation
Arm Type
Active Comparator
Arm Description
PVI ablation with additional CFAE and/or linear LA ablation
Intervention Type
Procedure
Intervention Name(s)
Ablation
Primary Outcome Measure Information:
Title
Freedom of atrial fibrillation/flutter
Time Frame
One year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Symptomatic persistent AF Failure of class I antiarrhythmic drug or amiodarone to control AF Exclusion Criteria: Previous proarrhythmia to class III AAD including excessive QT prolongation or torsade-de-pointes Previous AF ablation procedure Congestive heart failure (NYHA III-IV functional class) Left ventricle ejection fraction less than 35% Left atrial diameter >55 mm Unwillingness to participate
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jonathan S Steinberg, MD
Organizational Affiliation
Valley Health System/Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Valley Hospital
City
Ridgewood
State/Province
New Jersey
ZIP/Postal Code
07450
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Comparison of Reverse Remodeling and PVI Versus CFAE and/or Linear Lesions and PVI for Persistent AF

We'll reach out to this number within 24 hrs